If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCoca-Cola HBC Regulatory News (CCH)

Share Price Information for Coca-Cola HBC (CCH)

Share Price is delayed by 15 minutes
Get Live Data
5,170.00    30.00 (0.58%)
Bid:
5,160.00
Ask:
5,165.00
Spread: 5.00 (0.097%)
Market Cap: £18.84b
CCH Live PriceLast checked at - London Stock Exchange

Intraday Coca-Cola HBC Share Chart

Covid-19 update and actions

27 Mar 2020 07:00

RNS Number : 8413H
Coca-Cola HBC AG
27 March 2020
 

Coca-Cola HBC AG

Covid-19 update and actions

 

Zug, Switzerland - 27 March 2020 - On 19 March 2020, in connection with the release of our 2019 Annual Report and full year 2019 audited results announcement, Coca-Cola HBC acknowledged the COVID-19 outbreak and its potential greater impact in people's life, communities and global economy.

 

The COVID-19 global pandemic is an unprecedented event that will in some way touch everybody on the planet. As a food and beverage business, we have a recognised and important role to play in this crisis. The safety of our employees, customers, partners, consumers and products remains our highest priority. Wherever and whenever we can, we are actively supporting those who continue to have their lives changed or impacted by the virus, and those who are tirelessly and selflessly supporting the affected. We remain incredibly grateful for the extraordinary efforts that all our people are making in ensuring business continuity and continued product supply to our customers.

In parallel, we have implemented appropriate contingency and business continuity plans in order to safeguard that our production plants and supply chain remain fully operational. We have implemented global best-practice precautionary and hygiene measures at all our locations, including even stricter sanitation protocols, social distancing, travel restrictions and, where possible, our people are working from home. To-date this has meant that our supply chain is operational. As we move forward and governments step up their efforts to control the spread of COVID-19 we may see some disruption, although the extent and duration is unknown.

 

Current trading

 

Trading in January and February was in line with our expectations. During March, trading across our markets has been dependant on the severity of restrictions on mobility. In markets with heavy restrictions, such as Italy as well as central and southern Europe, demand in the 'out of home' channel has been severely affected. In these markets, 'out of home' represents c. 35-40% of sales.

 

Given this situation, we are already looking at cost-saving measures and reassessing marketing and capex investments. These actions will help to support our profitability.

 

It is still too early to quantify the impact that the COVID-19 pandemic will have on our full year 2020 results. Given the uncertainty of the duration and economic impact of this global pandemic, we no longer believe that it is prudent to provide guidance for the current financial year.

 

 

 

 

Balance sheet and liquidity

 

We benefit from a very strong balance sheet and have adequate liquidity for working capital and investment needs. As of the end of 2019, our net debt to EBITDA ratio was 1.54x. None of our debt facilities are subject to any financial covenants that would impact the Group's liquidity or access to capital. Therefore, as things stand, it remains the Board's intention to propose an ordinary dividend of €0.62 per share to our shareholders in the June 2020 Annual General Meeting.

 

Our strong balance sheet and liquidity position, our leading market shares and largely variable cost base, together with our unique portfolio of brands and resilient and talented people will allow us to weather this unprecedented crisis. When we emerge, we will be able to focus on capturing the many opportunities that we have in front of us. In the meantime, we continue to monitor the COVID-19 pandemic and its impact on our business and will provide further updates as necessary.

 

 

 

Enquiries

Coca‑Cola HBC Group

Investors and Analysts:

Joanna Kennedy

Investor Relations Director

Tel: +44 20 37 444 230

 joanna.kennedy@cchellenic.com

Carla Fabiano

Investor Relations Manager

Tel: +44 20 37 444 231

carla.fabiano@cchellenic.com

Media:

 

David Hart

Group External Communication Director

Tel: +41 41 726 0143

 david.hart@cchellenic.com

 

International media contact:

Teneo

Rob Morgan

Tom Davies

Tel: +44 7557 413 275

robert.morgan@teneo.com

tom.davies@teneo.com

 

 

Greek media contact:

V+O Communications

Argyro Oikonomou

Tel: +30 211 7501219

ao@vando.gr

 

 

 

About Coca‑Cola HBC

Coca-Cola HBC is a leading bottler of The Coca-Cola Company with an annual revenue in excess of €7 billion. It has a broad geographic footprint with operations in 28 countries serving a population of more than 600 million people. Coca-Cola HBC offers a diverse range of primarily non-alcoholic ready-to-drink beverages in the sparkling, juice, water, sport, energy, plant-based beverages and ready-to-drink tea and coffee categories. Coca-Cola HBC is committed to promoting sustainable development in order to create value for its business and for society. This includes providing products that meet the beverage needs of consumers, fostering an open and inclusive work environment, conducting its business in ways that protect and preserve the environment and contribute to the socio-economic development of the local communities. Coca-Cola HBC is ranked among the top sustainability performers in ESG benchmarks such as the Dow Jones Sustainability Indices, CDP, MSCI ESG and FTSE4Good, among others.

Coca-Cola HBC has a premium listing on the London Stock Exchange (LSE: CCH) and its shares are listed on the Athens Exchange (ATHEX: EEE). For more information, please visit http://www.coca-colahellenic.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
UPDFIFERVSIDFII
Date   Source Headline
2nd Jul 202612:20 pmRNSDirector Declaration
30th Jun 20262:45 pmRNSDirector/PDMR Shareholding
29th Jun 202612:45 pmRNSDirector/PDMR Shareholding
26th Jun 20269:15 amRNSDirector/PDMR Shareholding
26th Jun 20269:15 amRNSDirector/PDMR Shareholding
18th Jun 20263:15 pmRNSDirector/PDMR Shareholding
15th Jun 20265:00 pmRNSDirector/PDMR Shareholding
22nd May 20263:30 pmRNSDirector/PDMR Shareholding
19th May 20263:15 pmRNSDirector/PDMR Shareholding
11th May 20269:00 amRNSDirector Declaration
8th May 20263:15 pmRNSComposition of the Board Committees
8th May 20263:10 pmRNSResult of AGM
7th May 20267:00 amRNSStrong volume drives Q1 sales growth
20th Apr 20263:15 pmRNSDirector/PDMR Shareholding
14th Apr 202612:15 pmRNSNotice of Results
2nd Apr 20267:00 amRNSNotice of AGM, changes to the BoD, dividend dates
1st Apr 20269:15 amRNSTransfer of treasury shares & total voting rights
31st Mar 202611:00 amRNSPublication of Final Terms
27th Mar 20262:45 pmRNSDirector/PDMR Shareholding
27th Mar 20262:15 pmRNSDirector/PDMR Shareholding
26th Mar 20266:18 pmRNSPricing of Issue of Notes
26th Mar 20269:05 amRNSLaunch of Issue of Notes
25th Mar 20261:36 pmRNSPublication of a Prospectus
20th Mar 202611:00 amRNSAnnual Financial Report
19th Mar 20264:55 pmRNSDirector/PDMR Shareholding
19th Mar 20264:45 pmRNSDirector/PDMR Shareholding
18th Mar 20264:15 pmRNSDirector/PDMR Shareholding
18th Mar 202611:35 amRNSDirector/PDMR Shareholding
26th Feb 202611:30 amRNSDirector/PDMR Shareholding
25th Feb 20269:20 amRNSDirector/PDMR Shareholding
24th Feb 20264:55 pmRNSDirector/PDMR Shareholding
24th Feb 20264:50 pmRNSDirector/PDMR Shareholding
23rd Feb 20264:40 pmRNSDirector/PDMR Shareholding
23rd Feb 20264:35 pmRNSDirector/PDMR Shareholding
18th Feb 20264:50 pmRNSDirector/PDMR Shareholding
18th Feb 20264:45 pmRNSDirector/PDMR Shareholding
18th Feb 20264:00 pmRNSDirector/PDMR Shareholding
17th Feb 20263:35 pmRNSDirector/PDMR Shareholding
17th Feb 20263:30 pmRNSDirector/PDMR Shareholding
16th Feb 20262:40 pmRNSDirector/PDMR Shareholding
16th Feb 20262:35 pmRNSDirector/PDMR Shareholding
13th Feb 202610:30 amRNSDirector/PDMR Shareholding
12th Feb 20263:45 pmRNSDirector/PDMR Shareholding
12th Feb 20261:15 pmRNSDirector/PDMR Shareholding
10th Feb 20267:00 amRNSStrong execution and financial performance in 2025
2nd Feb 202610:00 amRNSTransfer of treasury shares & total voting rights
19th Jan 20264:00 pmRNSDirector/PDMR Shareholding
19th Jan 20262:20 pmRNSResult of Extraordinary General Meeting
13th Jan 202611:00 amRNSNotice of Results
5th Jan 202610:00 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.